Share on facebook
Share on twitter
Share on linkedin

December, 2014: BioAegis Establishes Collaboration with Vanderbilt and Northwestern to Measure Plasma Gelsolin Levels in Community-Acquired Pneumonia Patients

Data to Further Inform Design of Phase 2 Studies

BOSTON, MA and MORRISTOWN, NJ, (BIOAEGIS THERAPEUTICS) December, 2014 BioAegis Therapeutics Inc., a privately held biotechnology company exploiting plasma gelsolin’s (pGSN) role in immune function announced that it has established collaborations with Vanderbilt and Northwestern Universities to analyze plasma gelsolin levels in a well-adjudicated population of community-acquired pneumonia patients. These data will further inform the design of the company’s phase 2 trials.